• Benign Prostatic Hyperplasia
  • Hormone Therapy
  • Genomic Testing
  • Next-Generation Imaging
  • UTUC
  • OAB and Incontinence
  • Genitourinary Cancers
  • Kidney Cancer
  • Men's Health
  • Pediatrics
  • Female Urology
  • Sexual Dysfunction
  • Kidney Stones
  • Urologic Surgery
  • Bladder Cancer
  • Benign Conditions
  • Prostate Cancer

Dr. Gupta on toxicity management with enfortumab vedotin/pembrolizumab in urothelial carcinoma

Video

“It’s very important to really talk to the patients and understand any toxicities because the side effects are well managed if they’re caught early,” says Shilpa Gupta, MD.

Shilpa Gupta, MD, director of genitourinary medical oncology at Taussig Cancer Institute and co-leader of the Genitourinary Oncology Program at Cleveland Clinic, discusses toxicity management with the combination of pembrolizumab (Keytruda) and erdafitinib (Balversa) in patients with urothelial carcinoma. At the 2023 ASCO Annual Meeting, Gupta shared 4-year follow-up data from the EV-103 trial (abstract 4505), which continued to show rapid and durable response and promising survival trends with the combination in the front-line setting for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma. Gupta says if the ongoing EV-302 phase 3 trial (NCT04223856) firmly establishes pembrolizumab/erdafitinib as the new standard in this setting, successful management of adverse events will be critical to ensure patients can remain on this regimen.

Transcript

The key here is that with the use of the enfortumab vedotin/pembrolizumab combination, especially with the use of enfortumab vedotin, there can be toxicities like peripheral neuropathy, which can become disabling and it takes a long time to resolve. However, if dose modifications and dose discontinuations are properly done, then one can control that. I think the understanding of this new regimen and the toxicities are very important because the rash and the peripheral neuropathy can be challenging. So it's very important to really talk to the patients and understand any toxicities because it's well managed if it's caught early. So I think moving forward, if this becomes the standard, there's a lot of learning that needs to happen in terms of management of side effects.

Transcript has been edited for clarity.

Related Videos
Blur image of hospital corridor | Image Credit: © whyframeshot - stock.adobe.com
Gamal M. Ghoniem, MD, FACS, ABU/FPMRS, gives an answer during a video interview
Edward M. Schaeffer, MD, PhD, answers a question during a Zoom video interview
Zhina Sadeghi, MD, answers a question during a video interview
A panel of 4 experts on prostate cancer
A panel of 4 experts on prostate cancer
A panel of 5 experts on bladder cancer
A panel of 5 experts on bladder cancer
Related Content
© 2024 MJH Life Sciences

All rights reserved.